Drug Clinical Trials List

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
A Randomized, double-blind, placebo-controlled, multicenter phase III study of RAD001 Adjuvant Therapy in Poor Risk with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching PlaceboAfter Patients Have Achieved Complete Response with First-line Rituximab Chemotherapy	Novartis	Completed	Everolimus	3	CRAD001N2301	KFSH
"A randomized, double-blind, placebo-controlled phase III multi-center study of azacitidine with or without MBG453 for the treatment of patients with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)"	Novartis	Ongoing	MBG453 (sabatolimab)	3	CMBG453B12301	King Faisal Specialist Hospital and Research Center (Riyadh)
A randomized, double-blind, placebo-controlled phase II study to investigate the efficacy and safety of riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in patients with symptomatic pulmonary hypertension associated with idiopathic interstitial pneumonias (IIP).	Bayer	Completed	Riociguat	2	BAY 63-2521 / 13605	KFMC
A randomized, double-blind, parallel-group, multicenter study to assess efficacy, safety, and tolerability of oral tropifexor (LJN452) & licogliflozin (LIK066) combination therapy, compared to each monotherapy, for treatment of adult patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis (ELIVATE).	Novartis	Ongoing	LJN452	2b	CLJN452D12201C	King Fahad Medical City (Riyadh)
A Randomized, Double-blind, Multicenter, Phase III Study of Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced NET of GI or Lung Origin - RADIANT-4	Novartis	Completed	RAD001 (Everolimus, Afinitor)	3	CRAD001T2302	KFSH & RC-R
A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients with Low Tumor Burden Follicular Lymphoma	Archigen Biotech Limited	Completed	Rituximab / SAIT101	3	AGB 002	PSMMC
A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3-Arm, Parallel-Group Study in Pediatric Subjects Aged 10 Through 17 Years to Evaluate the Efficacy and Safety of BG00012 and BIIB017 for the Treatment of Relapsing-Remitting Multiple Sclerosis	Biogen	Completed	Dimethyl fumarate and PEGylated Interferon Beta-1a	3	800MS301	KKUH
A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis	Novartis	Ongoing	ofatumumab	3	COMB157G2301	KFSH&RC-J
A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler (MDI) Relative to Budesonide and Formoterol Fumarate MDI and Symbicort® Pressurized MDI in Adult and Adolescent Participants with Inadequately Controlled Asthma (LOGOS)	AstraZeneca	Ongoing	Budesonide, Glycopyrronium and Formoterol Fumarate	3	D5982C00008	King Abdulaziz University Hospital (Jeddah)
A randomized, double-blind placebo-controlled trial to evaluate the safety and efficacy of a SARS-CoV-2 inactivated vaccine among healthcare workers in Saudi Arabia	KAIMRC	Rejected	SARS-CoV-2 inactivated vaccine (Candidate vaccine) - Sinovac	3	RC20/370/R	King Abdulaziz Medical City NG (Riyadh)